Wondering if Regeneron Pharmaceuticals is a hidden gem or just fairly priced? You are not alone; investors everywhere are ...

According to Benzinga Pro, Regeneron Pharmaceuticals Inc's peer group average for short interest as a percentage of float is ...

Intellia Therapeutics also has fans on Wall Street. The company's current average price target of $32.3 (according to Yahoo!

OPKO Health recently reported third-quarter earnings with revenue of US$151.67 million and net income of US$21.63 million, surpassing analyst expectations, and announced a collaboration with Regeneron ...

Analysts expect Vertex Pharmaceuticals to report an earnings per share (EPS) of $4.35. Investors in Vertex Pharmaceuticals are eagerly awaiting the company's announcement, hoping for news of ...

Michael Burry boosted his positions in apparel, healthcare, and scientific stocks, while trimming major holdings, showing a ...

Discover Harrow Inc.'s growth strategy, bullish long-term prospects, and Q3 earnings outlook in ophthalmology. Click for more ...

Google’s parent company received a relatively benign antitrust ruling that would not force Alphabet to sell its Chrome ...

Big Short investor Michael Burry makes significant short bets against Nvidia and Palantir, forecasting potential corrections ...

Vancouver, Canada, November 4th, 2025, FinanceWire Equity Insider News Commentary – The precision medicine sector reached $119 billion in ...

October 29, 2025OPKO Health, Inc. beats earnings expectations. Reported EPS is $0.03, expectations were $-0.02. Operator: Good afternoon, and welcome to the OPKO Health Third Quarter 2025 Financial ...

iShares Biotechnology ETF (IBB) offers targeted exposure to the U.S. biotechnology sector, providing investors with access to a broad basket of industry-leading biotech equities. The fund's strategy ...